Diabetic ketoacidosis with SGLT2 inhibitors

نویسندگان
چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors.

Recently, the U.S. Food and Drug Administration (FDA) issued a Drug Safety Communication that warns of an increased risk of diabetic ketoacidosis (DKA) with uncharacteristically mild to moderate glucose elevations (euglycemic DKA [euDKA]) associated with the use of all the approved sodium–glucose cotransporter 2 (SGLT2) inhibitors (1). This Communication was based on 20 clinical cases requiring...

متن کامل

Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors.

It is possible that SGLT2 inhibitors trigger euglycemic diabetic ketoacidosis in some patients. Possible mechanism of euglycemic DKA induced by SGLT2 inhibitors is illustrated.

متن کامل

SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors1

Background: Sodium glucose cotransporter-2 (SGLT2) inhibitors are recommended by the American Diabetes Association (ADA) for the treatment of type 2 diabetes as one of six second-line therapy options after initial therapy with metformin. In addition, they have been studied in combination with insulin as a potential option for treating patients with type 1 diabetes. These medications act by inhi...

متن کامل

SGLT2 Inhibitors and the Diabetic Kidney.

Diabetic nephropathy (DN) is the most common cause of end-stage renal disease worldwide. Blood glucose and blood pressure control reduce the risk of developing this complication; however, once DN is established, it is only possible to slow progression. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, the most recent glucose-lowering oral agents, may have the potential to exert nephroprotectio...

متن کامل

SGLT2 Inhibitors-Sweet Success for Diabetic Kidney Disease?

nents, can lead to de novo ESRD in subjects without identifiable ESRD risks. These data also increase the urgency to identify kidney toxic dietary components and if these components can promote ESRD even in subjects who have no identifiable risk factors. Diet remains a relatively underused component of the clinician’s armamentarium in the fight to prevent patients with CKD progressing to ESRD a...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: BMJ

سال: 2020

ISSN: 1756-1833

DOI: 10.1136/bmj.m4147